The partnership is aimed at identifying biomarkers that may lead to the development of a molecular companion diagnostic test to help identify patients likely to respond to a Sanofi investigational agent.
HTG’s qNPA technology measures mRNA and/or miRNA expression in formalin fixed paraffin embedded (FFPE) tumor samples, which permit clinicians to verify the presence of certain biomarkers relevant to patient selection and therapy.
HTG Molecular Diagnostics CEO TJ Johnson said: "We are pleased to be a partner with Sanofi in answering the need for personalized cancer treatments. qNPA offers options in diagnostics testing of FFPE tissues not available in other commercial technologies."